Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2026-07-08 17:15:48 ET · period of report 2026-07-06 · accession 0001536368-26-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-07-08 17:15	2026-07-06	ELVN	Kunkel Lori Anne	Dir	S - Sale	$50.49	-10.0K	41.9K	-19%	-$504.9K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-07-06	S	D	4,111	$49.98	47,773	D	—	—	(F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 (F2) This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
2	Common	Common Stock	2026-07-06	S	D	5,889	$50.84	41,884	D	—	—	(F1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 (F3) This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.